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Abstract
Background: The zinc-finger antiviral protein (ZAP) is a host factor that specifically inhibits the replication of certain viruses,
including Moloney murine leukemia virus (MoMLV), HIV-1, and certain alphaviruses and filoviruses. ZAP binds to specific
viral mRNAs and recruits cellular mRNA degradation machinery to degrade the target RNA. The common features of ZAP-
responsive RNA sequences remain elusive and thus whether a virus is susceptible to ZAP can only be determined
experimentally. Xenotropic murine leukemia virus-related virus (XMRV) is a recently identified c-retrovirus that was originally
thought to be involved in prostate cancer and chronic fatigue syndrome but recently proved to be a laboratory artefact.
Nonetheless, XMRV as a new retrovirus has been extensively studied. Since XMRV and MoMLV share only 67.9% sequence
identity in the 39UTRs, which is the target sequence of ZAP in MoMLV, whether XMRV is susceptible to ZAP remains to be
determined.
Findings: We constructed an XMRV-luc vector, in which the coding sequences of Gag-Pol and part of Env were replaced
with luciferase-coding sequence. Overexpression of ZAP potently inhibited the expression of XMRV-luc in a ZAP expression-
level-dependent manner, while downregulation of endogenous ZAP rendered cells more sensitive to infection.
Furthermore, ZAP inhibited the spreading of replication-competent XMRV. Consistent with the previously reported
mechanisms by which ZAP inhibits viral infection, ZAP significantly inhibited the accumulation of XMRV-luc mRNA in the
cytoplasm. The ZAP-responsive element in XMRV mRNA was mapped to the 39UTR.
Conclusions: ZAP inhibits XMRV replication by preventing the accumulation of viral mRNA in the cytoplasm.
Documentation of ZAP inhibiting XMRV helps to broaden the spectrum of ZAP’s antiviral activity. Comparison of the
target sequences of ZAP in XMRV and MoMLV helps to better understand the features of ZAP-responsive elements.
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Introduction
The zinc-finger antiviral protein (ZAP) was initially recovered as
ahostfactorthatinhibitsMoloneymurineleukemiavirus(MoMLV)
infection[1].InadditiontoMoMLV,ZAPinhibitsthereplicationof
HIV-1, certain alphaviruses and filoviruses [2,3,4]. However, ZAP
does not induce a universal antiviral state because some viruses
replicate normally in ZAP-expressing cells [2].
Analyses for the step at which ZAP blocks MoMLV replication
reveal that ZAP prevents viral mRNA accumulation in the
cytoplasm without affecting the formation and nuclear entry of the
viral DNA [1]. Further studies demonstrate that ZAP directly
binds to specific viral mRNAs [3,4,5], recruits polyA ribonuclease
(PARN) to shorten the polyA tail [4], and recruits the RNA
exosome to degrade the RNA body from the 39 end [4,6]. In
addition, ZAP recruits the cellular decapping complex to initiate
degradation of the target viral mRNA from the 59 end [4]. The
DEAD-box RNA helicase p72 directly interacts with ZAP and is
required for optimal function of ZAP [7].
Whether a virus is sensitive to ZAP seems to be determined by
the presence of ZAP-responsive element (ZRE) in the viral mRNA.
The ZRE in MoMLV was mapped to the 39UTR and the ZREs in
SINV were mapped to multiple fragments [5]. For Ebola virus and
Marburg virus the ZRE was mapped to the L domain [3], and the
ZREs of HIV-1 were mapped to the 59UTRs of multiply spliced
mRNAs [4]. The only common feature of these ZAP target
sequences is that they are all more than 500 nt long; no obvious
common sequence or motifs can be identified in these ZREs. Thus
whether a virus is susceptible to ZAP can only be determined
experimentally.
Xenotropic murine leukemia virus-related virus (XMRV), a c-
retrovirus, was originally thought to be involved in prostate cancer
in a cohort of patients lacking a functional RNaseL gene [8].
However, in the follow up studies, little or no XMRV was detected
in patients with prostate cancer, raising questions on XMRV’s role
in prostate cancer [9,10,11,12]. XMRV was also thought to be
involved in chronic fatigue syndrome (CFS) [13]. Subsequent
analyses by laboratories from many countries, however, reported
the absence of XMRV infection in CFS patients [14,15,16,17],
and re-examinations of samples from patients previously identified
as XMRV-positive in the original study found no consistent
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serious doubt on the relationship between XMRV and human
diseases. In late 2011, strong evidence was provided that the virus
was just a laboratory artefact generated by recombination of two
mouse viruses during passage of a human prostate-tumour
xenograft [19]. Detection of the virus in patient samples is likely
laboratory contamination with XMRV produced by a prostate
cancer cell line or with other commercial laboratory reagents
[17,19]. Nonetheless, XMRV has been extensively studied as
a new retrovirus [20,21,22,23,24]. Comparison of XMRV with
related retroviruses provides insights into the detailed mechanisms
for retroviral replication.
In this report we show that human ZAP inhibits XMRV
infection by preventing the accumulation of viral mRNA in the
cytoplasm.
Results
1. Overexpression of hZAP inhibits XMRV infection
Due to the similarity between XMRV and MoMLV, we
speculated that ZAP might inhibit XMRV by the same
mechanism as it inhibits MoMLV. To facilitate sample handling
and detection of viral infection, we constructed an XMRV vector
carrying the firefly luciferase reporter gene. Since ZAP inhibits the
expression of MLV-luc vector, the XMRV reporter was generated
in a similar manner as constructing MLV-luc [5]. The coding
sequences of Gag-Pol and part of the envelope protein of XMRV
were replaced with the luciferase coding sequence to generate
pXMRV-luc (Fig. 1A). XMRV-luc pseudovirus was produced by
cotransfecting pXMRV-luc with plasmids expressing VSVG and
MLV Gag-pol into HEK 293T cells.
There are two forms of human ZAP (hZAP) arising from
alternative splicing, which differ only at the C-terminal domain
[25]. Myc-tagged full-length ZAP (hZAP-v1) and the short form
(hZAP-v2) were expressed in HEK293 cells in a tetracycline-
inducible manner. To test whether XMRV is sensitive to ZAP, the
cells were challenged with XMRV-luc and assayed for luciferase
expression with or without ZAP expression. The expression of
both hZAP-v1 and hZAP-v2 inhibited the expression of XMRV-
luc (Fig. 1B).
To assess whether ZAP’s inhibitory effect on XMRV-luc is
dependent on the expression level of ZAP, hZAP-v2 expression
was induced by increasing concentrations of tetracycline. With the
increasing expression level of hZAP-v2, fold inhibition of hZAP-v2
against XMRV-luc increased accordingly (Fig. 1C), indicating the
antiviral activity of hZAP-v2 against XMRV-luc is dependent on
the expression level of ZAP.
To test whether ZAP is able to inhibit the replication of XMRV,
replication-competent virus was produced by transfecting XMRV
proviral DNA into HEK 293T cells. 293Trex-hZAP-v2 cells were
infected with XMRV, followed by treatment of the cells with
doxycycline to induce ZAP expression. Virus spreading was
monitored by measuring reverse transcriptase (RT) activity in the
cell culture supernatants. In the absence of ZAP expression, the
peak RT activity was detected at 10 days postinfection (Fig. 1D),
which is consistent with the report that XMRV replicates
relatively poorly in HEK 293T cells [20]. In contrast, when
ZAP expression was induced, only very weak signal was detected
(Fig. 1D). These results indicate that ZAP inhibits the propagation
of replication-competent XMRV.
2. Downregulation of endogenous hZAP enhances
XMRV-luc infection
To test whether endogenous hZAP inhibits XMRV-luc, HOS
cells were transfected with siRNAs directed against hZAP (ZAPi-1
and ZAPi-2) to downregulate endogenous ZAP expression, and
then challenged with XMRV-luc. The ZAP mRNA levels were
downregulated by about 60% (Fig. 2A). As expected, the
expression of XMRV-luc was significantly increased in cells
transfected with the siRNAs directed against ZAP compared with
control cells (Fig. 2B), indicating that endogenous hZAP was active
against XMRV-luc infection.
3. Expression of hZAP prevents the accumulation of
XMRV-luc mRNA
ZAP has been demonstrated to inhibit MoMLV infection by
promoting viral mRNA degradation in the cytoplasm without
affecting the formation and nuclear entry of the viral DNA [1]. To
confirm that ZAP inhibits XMRV by the same mechanism,
293TRex-hZAP-v2 cells were infected with XMRV-luc at
different dilutions, and the nuclear circular viral DNA was
analyzed by PCR amplification. As expected, comparable levels of
the nuclear circular DNA were detected before and after induction
of hZAP expression (Fig. S1).
To analyze whether hZAP promotes XMRV mRNA degrada-
tion, 293Trex-hZAP-v2 cells were infected with XMRV-luc and
cultured for an extensive period of time to establish stable
infection. ZAP expression significantly inhibited XMRV-luc
expression (Fig. 3A). Consistently, XMRV-luc mRNA levels were
significantly reduced after the induction of ZAP expression, as
measured by Northern blotting (Fig. 3B).
ZAPs was recently reported to stimulate type I interferon
production through interaction with RIG-I [26]. To explore
whether ZAP inhibits XMRV infection by activating the RIG-I
pathway, endogenous RIG-I expression was downregulated in
293Trex-hZAP-v2 cells by RNAi (Fig. 4A). Downregulation of
RIG-I impaired poly (I:C)-activated IFNb-luc reporter expression
(Fig. 4B), but had little effect on the antiviral activity of ZAP
against XMRV (Fig. 4C), implicating that inhibition of XMRV
infection by ZAP is independent of the RIG-I pathway.
4. ZAP targets 39UTR of XMRV
Previous studies demonstrate that ZAP targets specific viral
mRNA sequences [5]. To identify the ZAP-responsive element
(ZRE) in XMRV, the sequence corresponding to the 59 or 39 UTR
of XMRV-luc was cloned into pHR’-CMV-luc (Fig. 5A),
a lentivector that is not responsive to ZAP [4]. The vectors were
packaged to infect 293TRex-hZAP-v2 cells and assayed for their
sensitivities to ZAP. The vector containing the 39UTR sequence
displayed sensitivity comparable to that of XMRV-luc. In contrast,
the vector containing the 59UTR failed to do so (Fig. 5B). These
results established that the 39UTR of XMRV-luc is the target
sequence of ZAP.
The ZRE in MoMLV was also mapped to the 39UTR [5].
Sequence analysis reveals that the 39UTRs of XMRV and
MoMLV share 67.9% identity (Fig. S2). To map the minimal
sequence required for response to ZAP, the 39UTR of XMRV was
truncated and the truncation mutants were analyzed for their
sensitivity to ZAP (Fig. 6A). The above identified XMRV 39UTR
covers a short fragment of env, U3 and the R region. Deletion of
the env sequence and R region did not significantly affect the
sensitivity to ZAP (Fig. 6B). However, further deletion resulted in
a significant drop in the sensitivity (Fig. 6B), suggesting that the
fragment covering the U3 region is the ZRE in XMRV.
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PLoS ONE | www.plosone.org 2 June 2012 | Volume 7 | Issue 6 | e39159Figure 1. Overexpression of hZAP inhibits XMRV infection. (A) Schematic structure of XMRV-luc vector. The coding sequences of Gag-Pol and
part of Envelope were replaced with luciferase-coding sequence to generate pXMRV-luc. (B) Overexpression of hZAP inhibits XMRV-luc infection.
293TRex cells expressing hZAP-v1-myc and hZAP-v2-myc upon tetracycline induction were infected with VSV-G pseudotyped XMRV-luc. Cells were
equally divided into two dishes at 6 h postinfection, with one mock treated and the other treated with tetracycline. Cells were lysed and luciferase
activity was measured at 48 h postinfection (upper panel). The luciferase activity in the absence of ZAP was set as 100. Data presented are means 6
SD of three independent experiments. The expression of hZAP was confirmed by Western blotting (lower panel). (C) ZAP inhibits XMRV-luc in an
expression-level-dependent manner. 293TREx-hZAP-v2 cells were infected with XMRV-luc. At 6 h postinfection the cells were equally split and
tetracycline was added to the concentrations indicated. Cells were lysed and luciferase activity was measured at 48 h postinfection. Fold inhibition
was calculated as the luciferase activity in mock treated cells divided by the luciferase activity in the tetracycline treated cells (upper panel). Data
presented are means 6 SD of three independent experiments. The expression levels of hZAP-v2 were measured by Western blotting (lower panel).
(D) ZAP inhibits XMRV replication. 293Trex-hZAP-v2 Cells were infected with XMRV produced in 293T cells. At 8 h postinfection, cells were mock
treated or treated with doxycycline to induce hZAP-v2 expression. Samples were taken every day and subjected to RT assays.
doi:10.1371/journal.pone.0039159.g001
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Infection of cells by retroviruses can be restricted by host factors
through a variety of mechanisms [27]. APOBEC3G and some of
its family members primarily target the single-stranded viral DNA
generated during reverse transcription [28]. TRIM5a targets
HIV-1 capsid (CA) and thus blocks viral infection in the early
phase [29]. Friend-virus susceptibility factor 1 (Fv1) also
inactivates the incoming viral capsids after entry [30]. Tetherin
inhibits the release of HIV-1 particles from the infected host cells
by ‘‘tethering’’ the nascent retroviral particles to the plasma
membrane [31]. Recently, several restriction factors have been
demonstrated to significantly inhibit the replication of XMRV,
including APOBEC3, Fv1 and Tetherin [21]. However Trim5a,
which inhibits N-tropic MLV, failed to inhibit XMRV infection
[21]. Hence, whether XMRV is restricted by a given factor seems
to require experimental determination.
ZAP has been reported to inhibit the infection of MoMLV,HIV-
1, Ebola virus, Marburg virus and certain alphaviruses [1,2,3,4]. In
the present study, we report that ZAP inhibits the expression of
XMRV vector and the propagation of replication-competent
XMRV. Consistent with the previously reported mechanisms by
which ZAP inhibits viral infection, ZAP significantly inhibited the
accumulation of XMRV-luc mRNA in the cytoplasm.
ZAP binds directly to ZRE-containing viral mRNAs. No
obvious common motifs or secondary structures have been
observed in the so far identified ZREs. The crystal structure of
the N-terminal domain of ZAP, the putative major RNA-binding
domain, predicts that the target RNA should have a tertiary
structure to place some nucleotides in the correct position to fit
into a three-dimensional cleft on ZAP surface [32]. Furthermore,
two ZAP-binding modules are required for a ZAP-responsive
RNA [32]. The ZAP responsive element (ZRE) in XMRV mRNA
was mapped to the 39UTR (Fig. 5A, B). Further mapping results
suggest that the ZRE of XMRV is in the 420bp fragment covering
the U3 region (Fig. 6B). Comparison of the 39UTRs of XMRV
and MoMLV provides some information about the sequences
required for the RNA to be responsive to ZAP (Fig. S2). For
example, the majority of the enhancer 1 region of MoMLV is
missing in XMRV, suggesting that this region is not required for
Figure 2. Downregulation of endogenous hZAP enhances XMRV-luc expression. HOS cells were transfected with control siRNA (Ctrl) or
siRNAs directed against hZAP (ZAPi-1 and ZAPi-2), followed by infection with XMRV-luc for 5 h. At 48 h postinfection, cells were lysed. (A)
Endogenous hZAP mRNA levels were measured by real-time PCR. (B) Luciferase activity was measured and presented as relative light units (RLU).
Data presented are means 6 SD of three measurements.
doi:10.1371/journal.pone.0039159.g002
Figure 3. Expression of hZAP prevents the accumulation of XMRV-luc mRNA. 293TRex-hZAP-v2 cells harbouring XMRV-luc provirus were
mock treated or treated with 1mg/ml tetracycline for 48 h to induce ZAP expression. (A) Cells were lysed and luciferase activity was measured (upper
panel). Data presented are means 6 SD of three independent experiments. The expression of hZAP was confirmed by Western blotting (lower panel).
(B) Cytoplasmic RNA was extracted and subjected to Northern blotting to detect the mRNA indicated (upper panel). Expression of hZAP was
confirmed by Western blotting (lower panel).
doi:10.1371/journal.pone.0039159.g003
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39UTRs of MoMLV, XMRV, ecotropic MLV, amphotropic
MLV, xenotropic MLV and polytropic MLV reveals that the
39UTRs of amphotropic MLV and ecotropic MLV share more
than 80% identity to that of MoMLV and that the 39UTRs of
xenotropic MLVs and polytropic MLV shared more than 85%
identity to that of XMRV. Thus, we speculate that these MLVs
may all be sensitive to ZAP.
In summary, here we report that ZAP inhibits XMRV infection
by targeting the viral mRNA for degradation in the cytoplasm.
The ZRE in XMRV is mapped to the U3 region of the 39UTR.
Such findings broaden the antiviral spectrum of ZAP.
Materials and Methods
Plasmid construction
pCR2-TOPO-VP62, an infectious clone of XMRV was kindly
provided by Dr. Stephen P. Goff (Columbia University, Howard
Hughes Medical Institute) [20]. pXMRV-luc is an XMRV vector
carrying 59 LTR of XMRV, luciferase coding sequence and
39LTR of XMRV. The 59LTR of XMRV was PCR-amplified
with forward primer 5LTRup bearing an EcoRI site and reverse
primer 5LTRdown bearing a BamHI site. To generate the 39LTR
of XMRV, a PCR fragment generated using primers 3LTRup and
3LTRm3 was mixed with a PCR fragment generated using
primers 3LTRm5 and 3LTRdown, and PCR-amplified using
primers 3LTRup bearing a NotI site and 3LTRdown. The
luciferase-coding sequence was amplified from pMLV-luc [1]
with forward primer X-luc5 bearing a BamHI site and reverse
primer X-luc3 bearing a NotI site. To generate pXMRV-luc, the
PCR fragment of 39LTR was cloned into pMD18-T vector
(TaKaRa), followed by cloning the 59 LTR fragment upstream of
the 39LTR. The PCR-derived coding sequence of luciferase was
inserted between 59LTR and 39LTR. Sequences of the primers are
listed below with restriction sites capitalized:
5LTRup: 59-gGAATTCgctgaaagaccccaccataag;
5LTRdown: 59-cgGGATCCgtccctagatctcgagaacactt;
3LTRup: 59-aGCGGCCGCtttgtaaaagacagaatttcg;
3LTRm3: 59-gttgttagtttcgctttatctgagg;
3LTRm5: 59-cctcagataaagcgaaactaacaac;
3LTRdown: 59-caaatgaaagacccccgagctgggtag;
X-luc5: 59-cgGGATCCaccatggaagacgccaaaaacat;
X-luc3: 59-ccgcgtGCGGCCGCttacaatttggactttcc
pHR’-CMV-Luc, a lentivector that is not sensitive to ZAP, has
been described previously [33]. Plasmid pHR’-CMV-MCS-Luc
was modified from pHR’-CMV-Luc by deleting the BamHI site,
followed by inserting a fragment containing BamHI, EcoRI and
SalI sites between the CMV promoter and luciferase-coding
sequence. To generate pHR’-CMV-59 UTR-luc, the 59 UTR of
XMRV was PCR-amplified with forward primer UTR5-5 bearing
an EcoRI site and reverse primer UTR5-3 bearing a SalI site and
cloned into pHR’-CMV-MCS-Luc. To generate pHR’-CMV-luc-
39UTR, a fragment covering the luciferase-coding sequence and
39UTR of XMRV was amplified from pXMRV-luc with primers
Luc3-5 bearing a BamHI site and UTR3-3 bearing an XhoI site to
replace the BamHI-XhoI fragment of pHR’-CMV-MCS-Luc. The
39UTR truncation mutants were generated by PCR-amplification
of desired sequences with primers bearing an XhoI site upstream of
the matching sequences. The resulting fragments were inserted
into the XhoI site in pHR’-CMV-MCS-Luc. Sequences of the
primers are listed below with restriction sites capitalized.
UTR5-5: 59-aaGAATTCagccttttgctgtttgcatc
UTR5-3: 59-ttcaGTCGACggatccgtccctagatct
Luc3-5: 59-ggacggatccaccatggaagacgccaa
UTR3-3: 59-ccagCTCGAGtgggaacacgggtacccg
Sd1-F: 59- agCCGCTCGAGattttattcagtttc
Sd2-F: 59-agCCGCTCGAGttctcaaaagttacaag
Sd-R: 59-ccagCTCGAGtgggaacacgggtacccg
Ad-F: 59-agCCGCTCGAGtgtaaaagacagaatttc
Ad1-R: 59-agCCGCTCGAGgccgagtgtggagttc
AD2-R: 59-agCCGCTCGAGaaactgttgttagt
The plasmids expressing shRNAs directed against RIG-I (Ri446
and Ri538) and a control shRNA were generated by annealing
pairs of oligonucleotides and cloning into pSuper-retro-puro
(OligoEngine) using BglII and HindIII sites following the
manufacture’s instructions. The target sequences are listed below.
Control: 59-GCAAGCTGACCCTGAAG
Figure 4. Downregulation of RIG-I does not affect ZAP’s
antiviral activity against XMRV-luc. (A) Control shRNA and shRNAs
against RIG-I (Ri446 and Ri583) were stably expressed in 293TRex-hZAP-
v2 cells. RIG-I mRNA levels were measured by real-time PCR and
normalized to that of GAPDH. Data presented are means 6 SE of three
parallel experiments. (B) Cells were transfected with pGl3-IFNb-luc and
pRL-TK. At 48 h posttransfection, cells were transfected with poly (I:C).
Luciferase activity was assayed 12 h later. (C) Cells were infected with
XMRV-luc, mock treated or treated with tetracycline for 48 h to induce
ZAP expression, and luciferase activities were measured. Fold inhibition
was calculated as the luciferase activity in mock treated cells divided by
that in tetracycline treated cells. Data presented are means 6 SE of
three parallel experiments.
doi:10.1371/journal.pone.0039159.g004
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shRIGi538: 59-GCAAGATCTTACTCAGAGA
pcDNA4TO/myc-hZAP-v1 and pcDNA4TO/myc-hZAP-v2,
which express myc-tagged hZAP-v1 and hZAP-v2, respectively,
have been describes previously [4].
siRNA and siRNA transfection
Control siRNA (siCtrl: Catalog No. D-001810-10) and siRNAs
against hZAP (ZAPi-1: Catalog No. J-017449-11 and siZAPi-2:
Catalog No. J-017449-09) were obtained from Thermo Scientific.
siRNA was transfected into cells by lipofectamine 2000 (Invitro-
gen) following the manufacturer’s protocol.
Cells and viral infection
All the cells were maintained in DMEM supplemented with10%
FBS. Transfection was performed using lipofectimine 2000
(Invitrogen) following the manufacturer’s instruction. 293TRex-
hZAP-v1 and 293TRex-hZAP-v2 cells have been described
previously [4].
Production of VSV-G pseudotyped SR-Ctrl, SR-RIG-Ii446 and
SR-RIG-Ii583 transducing viruses, and transduction of 293TRex-
hZAP-v2 cells with these viruses have been previously reported [4].
VSV-G pseudotyped XMRV-luc was produced by cotransfec-
tion of 293T cells with pVSV-G, pHIT60 and the XMRV-luc
vector. To produce VSV-G pseudotyped lentiviruses, 293T cells
were cotransfected with pVSV-G and pCMVdelR8.2 (a plasmid
expressing HIV Gag and Pol proteins), and pHR’-CMV-mcs-luc
vectors.
Replication-competent XMRV was produced by transfection of
293T cells with pCR2-TOPO-VP62. Plasmid pVSVG was
included to enhance XMRV infection efficiency.
To evaluate the antiviral activity of ZAP, cells were infected
with XMRV-luc or HR’-CMV-mcs-luc based vectors. At 5 h
postinfection, cells were equally divided into two dishes, with one
mock treated and the other treated with tetracycline. The cells
were lysed and luciferase activities were measured with the
Figure 5. ZAP targets the 39LTR of XMRV. (A) Schematic structures of HR’-CMV-luc vectors. (B) 293TRex-hZAP-v2 cells were infected with the
vectors indicated. At 3 h postinfection, cells were mock treated or treated with 1 mg/ml tetracycline to induce ZAP expression. At 48 h postinfection
the cells were lysed and luciferase activity was measured. Fold inhibition was calculated as luciferase activity in mock treated cells divided by
luciferase activity in tetracycline treated cells (up panel). Data presented are means 6 SD of three independent experiments. The expression of hZAP-
v2 was confirmed by Western blotting (lower panel).
doi:10.1371/journal.pone.0039159.g005
ZAP Inhibits XMRV Infection
PLoS ONE | www.plosone.org 6 June 2012 | Volume 7 | Issue 6 | e39159Luciferase Assay System (Promega) at 48 h postinfection. Fold
inhibition was calculated as the luciferase activity in mock treated
cells divided by that in tetracycline treated cells.
To establish a 293Trex-hZAP-v2 cell line carrying XMRV-luc
provirus, 293Trex-hZAP-v2 cells were infected for 4 times with
XMRV-luc, followed by cultivation and passage for a week.
Hirt DNA extraction and detection of nuclear circular viral
DNA
293TRex-hZAP-v2 cells were seeded in 35 mm dishes and
infected with XMRV-luc viruses at varying dilution on the next
day. Right after infection the cells were untreated or treated with
tetracycline to induce hZAP-v2 expression. At 24 h postinfection,
Hirt DNA was extracted as described previously [34], and the
nuclear circular DNA was detected by PCR-amplification of the 2-
LTR junction using primers X2LTR5 and X2LTR5. Mitochon-
drion DNA (mtDNA) amplified with primers hmtDNAsp and
hmtDNAap were used as an internal control. PCR conditions
were 94uC for 30 s, 57uC for 30 s, and 72uC for 45 s for 40 cycles.
Sequences of the primers are listed below.
X2LTR5: 59-agtcatccgatagactgag
X2LTR3: 59-ttatagggctaggactggg
hMtDNAsp: 59-GACGTTAGGTCAAGGTGTAG
hMtDNAap: 59-GGTTGTCTGGTAGTAAGGTG
Real-time PCR
Cytoplasmic RNA was extracted using RNeasy Kit (Qiagen)
following the manufacturer’s instruction, followed by reverse
transcription with MLV reverse transcriptase using random
primers. The mRNA levels of hZAP and RIG-I were measured by
SYBR Green real-time PCR in Rotor-gene 6000 (Corbett Life
Science) using the following program: 1) 50uC 2 min, 1 cycle; 2)
95uC 5 min, 1 cycle; 3) 95uC1 5s- . 60uC3 0s- . 72uC3 0s ,4 0
cycles; 4) 72uC 10 min, 1 cycle. The mRNA level of gapdh served as
the internal control. The sequences of the primers are listed below:
qhZAP FP: CCACATCTTCTAGGGTGGATGA
qhZAP RP: CGTCCAGGTTTTACCAATAAGCA
qRIG-I FP: CCTACCTACATCCTGAGCTACAT
qRIG-I RP: TCTAGGGCATCCAAAAAGCCA
qGAPDH FP: ATGGGGAAGGTGAAGGTCG
qGAPDH RP:GGGGTCATTGATGGCAACAATA
XMRV spreading assay
293Trex-hZAP-v2 Cells were seeded in 60 mm disks and
infected the day after with 2 ml XMRV virus produced in 293T
cells. At 8 h postinfection, cells were mock treated or treated with
doxycycline to induce expression of hZAP-v2. Supernatants were
collected every day and subjected to RT assays as described
previously [35].
Northern blotting
Cytoplasmic RNA was isolated from cells with an RNeasy kit
(Qiagen) according to the manufacturer’s instructions. The RNA
samples were separated by electrophoresis, transferred to nylon
membrane, and hybridized for 15–20 h with 32P-labeled probes
preparedbyarandomprimerlabelingkit(Stratagene,LaJolla,CA).
The probe for XMRV-luc mRNA was the coding sequence of firefly
luciferase. The probe for gapdh mRNA was the coding sequence of
gapdh. The nylon membrane was washed three times with 0.16SSC
(pH 7) and 0.1% SDS at 65uC and exposed to x-ray film.
Figure 6. Mapping of ZRE in the 39 LTR of XMRV. (A) Schematic structures of the truncation constructs of 39UTR. (B) Analysis of the sensitivity of
the 39UTR truncation mutants to ZAP. Fold inhibition was measured as described in the legend to Figure 5B. Data presented are means 6 SD of three
independent experiments.
doi:10.1371/journal.pone.0039159.g006
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293TRex-hZAP-v2-Ctrl, 293TRex-hZAP-v2-Ri446, and
293TRex-hZAP-v2-Ri583 cells (,1610
5) were seeded on 24-well
plates and transfected with reporter plasmid pGL3-IFNb-luc (a
kind gift from Prof. Zhengfan Jiang, Peking University, China) on
the following day. To normalize transfection efficiency, 0.01 mgo f
pRL-TK Renilla reporter plasmid (Promega) was included in each
transfection. Cells were mock treated or treated with tetracycline
(1 mg/ml) to induce ZAP expression. At 48 h posttransfection, cells
were stimulated for 12 h by transfection of 0.25 mg poly (I:C), and
luciferase activity was measured with the Dual-Luciferase Re-
porter Assay system (Promega).
Supporting Information
Figure S1
hZAP does not block the formation and nuclear entry of
XMRV-luc proviral DNA. 293TREx-hZAP-v2 cells were
infected with XMRV-luc virus at the indicated dilutions. At 6 h
postinfection, cells were mock treated or treated with 1 mg/ml
tetracycline. At 24 h postinfection, cells were lysed and Hirt DNA
was extracted. The 2-LTR junction of the nuclear circular viral
DNA was detected by PCR. PCR product of mitochondrion DNA
(mtDNA) was used as an internal control. The data is
representative of three independent experiments.
(TIF)
Figure S2 Sequence comparison of the 39 UTRs of
different MLVs. The 39UTRs of XMRV, MoMLV
(AF033811), Friend MLV (NC_001362), amphotropic MLV
1313 (AF411814), xenotropic MLV LAPC4 (JF908816), xenotro-
pic MLV DG-75 (AF221065), polytropic MLV MCF 1233
(U13766) were aligned using Vector NTI 10.0.1. X, xenotropic;
P, polytropic; A, amphotropic; E, ecotropic.
(TIF)
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